Header

UZH-Logo

Maintenance Infos

Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumor bearing dogs


Athanasiadi, Ilektra; Geigy, Caroline; Hilgers, Ralf D; Meier, Valeria; Rohrer Bley, Carla (2017). Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumor bearing dogs. Veterinary and Comparative Oncology, 15(1):94-104.

Abstract

TriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use, carrying the triazene group as the cytotoxic principal. Using a standard 3 + 3 design, a phase I study was performed in tumour bearing dogs to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and pharmacokinetic (PK) profile of TriN 2755. Thirty dogs were included in the study. TriN 2755 was administered over 20 min on two consecutive weeks per month for a total of three cycles. The starting dose was 25 mg kg-1 and the MTD was 74.6 mg kg-1 . Three dogs experienced DLT, which was characterized by gastrointestinal adverse events. The PKs of TriN 2755 and its main metabolites in plasma and sputum are described in a two-compartment model. The response rate for 19 of 30 dogs was 47.3% (six partial remission, three stable disease) and the median progression-free interval (PFI) for the responders was 47 days (range: 21-450 days).

Abstract

TriN 2755 is an alkylating antineoplastic agent for intravenous (IV) use, carrying the triazene group as the cytotoxic principal. Using a standard 3 + 3 design, a phase I study was performed in tumour bearing dogs to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and pharmacokinetic (PK) profile of TriN 2755. Thirty dogs were included in the study. TriN 2755 was administered over 20 min on two consecutive weeks per month for a total of three cycles. The starting dose was 25 mg kg-1 and the MTD was 74.6 mg kg-1 . Three dogs experienced DLT, which was characterized by gastrointestinal adverse events. The PKs of TriN 2755 and its main metabolites in plasma and sputum are described in a two-compartment model. The response rate for 19 of 30 dogs was 47.3% (six partial remission, three stable disease) and the median progression-free interval (PFI) for the responders was 47 days (range: 21-450 days).

Statistics

Altmetrics

Downloads

9 downloads since deposited on 18 Dec 2015
8 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:05 Vetsuisse Faculty > Veterinary Clinic > Department of Small Animals
Dewey Decimal Classification:570 Life sciences; biology
630 Agriculture
Language:English
Date:2017
Deposited On:18 Dec 2015 15:14
Last Modified:08 Dec 2017 15:52
Publisher:Wiley-Blackwell Publishing, Inc.
ISSN:1476-5810
Additional Information:This is the accepted version of the following article: Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumor bearing dogs, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/vco.12145/abstract.
Publisher DOI:https://doi.org/10.1111/vco.12145
PubMed ID:25689225

Download

Download PDF  'Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumor bearing dogs'.
Preview
Content: Accepted Version
Language: English
Filetype: PDF
Size: 662kB
View at publisher